2. Search Result
Search Result
Results for "

intestinal transport

" in MedChemExpress (MCE) Product Catalog:

49

Inhibitors & Agonists

3

Biochemical Assay Reagents

6

Peptides

11

Natural
Products

6

Isotope-Labeled Compounds

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0113
    Omeprazole
    5+ Cited Publications

    H 16868

    		 Na+/K+ ATPase Proton Pump Bacterial Cytochrome P450 Apoptosis Autophagy Atg8/LC3 TNF Receptor Interleukin Related Infection Neurological Disease Inflammation/Immunology Cancer
    Omeprazole (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .
    Omeprazole
  • HY-N6684
    Deoxynivalenol
    15+ Cited Publications

    Vomitoxin

    		 P-glycoprotein Metabolic Disease
    Deoxynivalenol, an orally active mycotoxin of the trichothecenes family, crosses the intestinal mucosa by a paracellular pathway through the tight junctions. The Deoxynivalenol transport is not affected by P-glycoprotein (PgP) or multidrug resistance-associated proteins (MRPs) inhibitors .
    Deoxynivalenol
  • HY-B2132
    Tryptamine
    1 Publications Verification

    3-(2-Aminoethyl)indole~2-(3-Indolyl)ethylamine

    		 Endogenous Metabolite 5-HT Receptor Aryl Hydrocarbon Receptor Neurological Disease Metabolic Disease
    Tryptamine is a selective, blood-brain-penetrating 5-HT4 receptor agonist (EC50=1-3 mM) and an endogenous ligand of the aryl hydrocarbon receptor (AHR) (Kd=10-50 nM). Tryptamine promotes intestinal anion secretion and fluid transport by activating G protein-coupled receptors (GPCRs) and accelerates gastrointestinal motility. Tryptamine regulates Th17/Treg balance to inhibit neuroinflammation, competitively binds to 5-HT receptors to regulate central nervous system activity, and participates in temperature regulation and spinal reflex regulation as a neuromodulator. Tryptamine can be used to study intestinal motility disorders such as functional constipation, and has shown significant efficacy in multiple sclerosis models .
    Tryptamine
  • HY-148033
    Trimethyl chitosan

    N,N,N-Trimethylchitosan

    		 Drug Derivative Others
    Trimethyl chitosan (N,N,N-Trimethylchitosan) is a multifunctional polymer and a derivative of Chitosan (HY-B2144A). Trimethyl chitosan targets the absorption enhancing proteins of tight junctions of intestinal and mucosal epithelial cells, induces tight junction protein rearrangement, and increases intercellular permeability. Trimethyl chitosan can stimulate the activity of promoting transmembrane transport of hydrophilic drugs (such as peptides and proteins) and can be used for drug delivery and synthesis of nanoparticles .
    Trimethyl chitosan
  • HY-B0113A
    Omeprazole sodium
    5+ Cited Publications

    H 16868 sodium

    		 Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Inflammation/Immunology
    Omeprazole (H 16868) sodium is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole sodium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sodium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sodium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sodium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sodium aslo has neuroprotective and antibacterial effects .
    Omeprazole sodium
  • HY-W013061
    Propane-1,2,3-triyl tripalmitate

    		Endogenous Metabolite Metabolic Disease
    Propane-1,2,3-triyl tripalmitate is a saturated fat. Propane-1,2,3-triyl tripalmitate enhances the lymphatic transport of Glycerol tristearate (HY-127035) .
    Propane-1,2,3-triyl tripalmitate
  • HY-112624I
    Dextran T3 (MW 3,000)

    Dextran 3; Dextran D3; Dextran T3(MW 2400-3600)

    		 Bacterial Others
    Dextran T3 (Dextran 3; Dextran T3(MW 2400-3600)) is a neural tracer and intestinal permeability probe that can move anterogradely and retrogradely in neuronal axons by passive diffusion. Dextran T3 (MW 3,000) is able to permeate across the intestinal epithelial cell membrane in the presence of cholera toxin-induced cytoskeletal disturbance. Dextran T3 (MW 3,000) is used as a fluorescent marker to rapidly label developing neurons (such as Xenopus retinal ganglion cells) and to assess intestinal barrier function. It can be used to study axonal transport in neuroanatomy and permeability changes in intestinal pathophysiology. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance .
    Dextran T3 (MW 3,000)
  • HY-N0468
    Rebaudioside D
    1 Publications Verification

    		 FXR Acetyl-CoA Carboxylase Metabolic Disease
    Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .
    Rebaudioside D
  • HY-101086
    Acetylcholine iodide
    Maximum Cited Publications
    24 Publications Verification

    ACh iodide

    		 Endogenous Metabolite mAChR Neurological Disease Endocrinology
    Acetylcholine iodide is a muscarinic receptor modulator. Acetylcholine iodide specifically binds to muscarinic receptors, inhibits sodium absorption, and induces chloride secretion. Acetylcholine iodide changes intestinal ion transport, enhances intestinal secretory function, induces or maintains mammary gland development and lactation. Acetylcholine iodide can be used for intestinal ion transport regulation and mammary gland physiological function research .
    Acetylcholine iodide
  • HY-107969
    Haloperidol decanoate

    		Dopamine Receptor COX NO Synthase Neurological Disease Cancer
    Haloperidol decanoate is a depot preparation of haloperidol, a commonly used butyrophenone derivative with antipsychotic activity. Haloperidol decanoate can increase the striatal D2 receptor in rat. Haloperidol decanoate can improve conditions of psychoses (mainly schizophrenia). Haloperidol decanoate can lead to increased accumulation of the dopamine metabolites homo-vanillic acid. Haloperidol decanoate can reduce intestinal transport, increase gastric emptying and reduce acid output in rat model .
    Haloperidol decanoate
  • HY-B1264
    Celiprolol hydrochloride
    1 Publications Verification

    		 NO Synthase Adrenergic Receptor Cardiovascular Disease
    Celiprolol (REV 5320) is a potent, cardioselective and orally active β1-andrenoceptor r antagonist with partial β2 agonist activity, with Ki values of 0.14-8.3 μM. Celiprolol has antihypertensive and antianginal activity, and can be used for the research of cardiovascular disease such as high blood pressure .
    Celiprolol hydrochloride
  • HY-126584
    H-Val-Val-OH

    Val-Val

    		 Drug Intermediate Oligopeptide Cotransporter Others
    H-Val-Val-OH (Val-Val) is a stereochemistry-dependent substrate and inhibitor of apical oligopeptide transporters. H-Val-Val-OH undergoes apical intracellular accumulation in human intestinal cells via carrier-mediated transport, and inhibits the uptake of Cephalexin (HY-B0200) through interaction with transporters. Substitution of L-valine with D-valine in H-Val-Val-OH abolishes its binding ability to apical oligopeptide transporters .
    H-Val-Val-OH
  • HY-B0113R
    Omeprazole (Standard)

    H 16868 (Standard)

    		 Reference Standards Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Metabolic Disease Cancer
    Omeprazole (Standard) is the analytical standard of Omeprazole. This product is intended for research and analytical applications. Omeprazole (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .
    Omeprazole (Standard)
  • HY-B0113S
    Omeprazole-d3
    1 Publications Verification

    H 16868-d3

    		 Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Metabolic Disease Cancer
    Omeprazole-d3 (H 16868-d3) is deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .
    Omeprazole-d3
  • HY-P1179
    Guanylin(human)

    		Guanylate Cyclase Endogenous Metabolite Endocrinology Cancer
    Guanylin(human), a 15-amino acid peptide, is an endogenous intestinal guanylate cyclase activator. Guanylin(human) is mainly found in gastrointestinal tract which regulates electrolytead water transport in intestinal and renal epithelia through cyclic GMP-dependent mechanism .
    Guanylin(human)
  • HY-P1179A
    Guanylin(human) TFA

    		Guanylate Cyclase Endogenous Metabolite Metabolic Disease
    Guanylin(human) TFA, a 15-amino acid peptide, is an endogenous intestinal guanylate cyclase activator. Guanylin(human) TFA is mainly found in gastrointestinal tract which regulates electrolytead water transport in intestinal and renal epithelia through cyclic GMP-dependent mechanism .
    Guanylin(human) TFA
  • HY-154912
    PAT1inh-B01

    		Chloride Channel Inflammation/Immunology
    PAT1inh-B01 is a selective SLC26A6 inhibitor. PAT1inh-B01 inhibits PAT1 (a Cl -/HCO3 - exchanger)-mediated anion exchange (IC50: 350 nM). PAT1inh-B01 blocks fluid absorption in small intestine. PAT1inh-B01 can be used for research of small intestinal hyposecretory disorders .
    PAT1inh-B01
  • HY-131286A
    Talaglumetad (hydrochloride)

    LY-544344 (hydrochloride)

    		 Drug Derivative mGluR Neurological Disease
    Talaglumetad hydrochloride (LY-544344 hydrochloride) is an orally active prodrug of Eglumegad (HY-18941) and a metabotropic glutamate receptor 2/3 (mGluR2/3) agonist. Talaglumetad hydrochloride undergoes transmembrane transport via the intestinal peptide transporter hPepT1, and is enzymatically hydrolyzed to produce L-alanine and the parent drug Eglumegad after entering the body. Talaglumetad hydrochloride can be used in research related to metabotropic glutamate receptor 2-associated neurological systems .
    Talaglumetad (hydrochloride)
  • HY-15830
    25,26-Dihydroxyvitamin D3

    25,26-Dihydroxycholecalciferol

    		 VD/VDR Drug Metabolite Drug Derivative Calcium Channel Metabolic Disease
    25,26-Dihydroxyvitamin D3 (25,26-Dihydroxycholecalciferol) is a dihydroxylated derivative and metabolite of Vitamin D3 (HY-15398). 25,26-Dihydroxyvitamin D3 moderately increases serum calcium levels when the initial serum calcium level is low. 25,26-Dihydroxyvitamin D3 promotes intestinal calcium absorption in vitamin D-deficient rats fed a low-calcium diet. 25,26-Dihydroxyvitamin D3 is applicable to research related to osteomalacia .
    25,26-Dihydroxyvitamin D3
  • HY-109546
    Omeprazole magnesium

    		Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Metabolic Disease Cancer
    Omeprazole (H 16868) magnesium is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole magnesium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole magnesium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole magnesium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole magnesium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole magnesium aslo has neuroprotective and antibacterial effects .
    Omeprazole magnesium
  • HY-B0113S3
    Omeprazole-13C,d3

    H 16868-13C,d3

    		 Isotope-Labeled Compounds Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Metabolic Disease Cancer
    Omeprazole- 13C,d3 is a 13C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .
    Omeprazole-13C,d3
  • HY-130704
    Isotachysterol 3

    		Calcium Channel Metabolic Disease
    Isotachysterol 3 is an analog of 1,25-dihydrox Vitamin D3. Isotachysterol 3 stimulates intestinal calcium transport and bone calcium mobilization in anephric rats .
    Isotachysterol 3
  • HY-154912A
    PAT1inh-B01 hydrochloride

    		Chloride Channel Inflammation/Immunology
    PAT1inh-B01 hydrocholide is a selective SLC26A6 inhibitor. PAT1inh-B01 hydrocholide inhibits PAT1 (a Cl -/HCO3 - exchanger)-mediated anion exchange (IC50: 350 nM). PAT1inh-B01 hydrocholide blocks fluid absorption in small intestine. PAT1inh-B01 hydrocholide can be used for research of small intestinal hyposecretory disorders .
    PAT1inh-B01 hydrochloride
  • HY-154928
    GW6340

    		LXR Metabolic Disease
    GW6340 is an intestinal-specific LXR agonist. GW6340 promotes macrophage reverse cholesterol transport (mRCT) .
    GW6340
  • HY-179107
    SLC6A19-IN-3

    		Amino acid Transporter Metabolic Disease
    SLC6A19-IN-3 (Compound 83-P1-P2) is a potent, selective and orally active SLC6A19 inhibitor with an IC50 of 28 nM. SLC6A19-IN-3 can block SLC6A19-mediated transmembrane transport of phenylalanine, reducing intestinal absorption of phenylalanine from food and renal tubular reabsorption of phenylalanine. SLC6A19-IN-3 can be used for the research of metabolic disease, such as phenylketonuria .
    SLC6A19-IN-3
  • HY-168772
    Glycyl-L-Proline TFA

    H-Gly-Pro-OH TFA

    		 Amino Acid Derivatives Others
    Glycyl-L-Proline TFA (H-Gly-Pro-OH TFA) is a dipeptide, which is composed of a glycine and a L-proline. Glycyl-L-Proline TFA can be used in research about the co-relationship between transmembrane potential/proton gradient and intestinal transport .
    Glycyl-L-Proline TFA
  • HY-146391
    P-gp inhibitor 4

    		P-glycoprotein Cancer
    P-gp inhibitor 4 (Compound 8b) is a selective P-glycoprotein modulator with an EC50 of 94 nM. P-gp inhibitor 4 increases agent transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells .
    P-gp inhibitor 4
  • HY-N6684R
    Deoxynivalenol (Standard)

    Vomitoxin (Standard)

    		 P-glycoprotein Reference Standards Metabolic Disease
    Deoxynivalenol (Standard) is the analytical standard of Deoxynivalenol. This product is intended for research and analytical applications. Deoxynivalenol, an orally active mycotoxin of the trichothecenes family, crosses the intestinal mucosa by a paracellular pathway through the tight junctions. The Deoxynivalenol transport is not affected by P-glycoprotein (PgP) or multidrug resistance-associated proteins (MRPs) inhibitors .
    Deoxynivalenol (Standard)
  • HY-119873
    Celiprolol

    REV 5320

    		 NO Synthase Adrenergic Receptor Cardiovascular Disease
    Celiprolol (REV 5320) is a potent, cardioselective and orally active β1-andrenoceptor r antagonist with partial β2 agonist activity, with Ki values of 0.14-8.3 μM. Celiprolol has antihypertensive and antianginal activity, and can be used for the research of cardiovascular disease such as high blood pressure .
    Celiprolol
  • HY-N0468R
    Rebaudioside D (Standard)

    		Reference Standards Acetyl-CoA Carboxylase FXR Metabolic Disease
    Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .
    Rebaudioside D (Standard)
  • HY-124218
    S 863390

    		Antibiotic Others
    S 863390 is a compound with the ability to inhibit the intestinal uptake system, which can interact with the intestinal uptake system to inhibit the uptake of β-lactam antibiotics and small peptides while also being transported itself.
    S 863390
  • HY-E70729
    ICK Recombinant Human Active Protein Kinase

    		Ser/Thr Kinase Metabolic Disease
    The intestinal cell kinase (ICK) protein belongs to the ros-cross hybridizing kinase (RCK) family. ICK is a ciliary protein, involved in ciliogenesis and regulation of intraflagellar transport (IFT). ICK Recombinant Human Active Protein Kinase is a recombinant ICK protein that can be used to study ICK-related functions .
    ICK Recombinant Human Active Protein Kinase
  • HY-N11422R
    Mycaminosyltylonolide (Standard)

    		Reference Standards Antibiotic Bacterial Infection
    Deoxynivalenol (Standard) is the analytical standard of Deoxynivalenol. This product is intended for research and analytical applications. Deoxynivalenol, an orally active mycotoxin of the trichothecenes family, crosses the intestinal mucosa by a paracellular pathway through the tight junctions. The Deoxynivalenol transport is not affected by P-glycoprotein (PgP) or multidrug resistance-associated proteins (MRPs) inhibitors .
    Mycaminosyltylonolide (Standard)
  • HY-W019868
    1-O-Hexadecyl-2-O-acetyl-sn-glycerol

    		mTOR Others
    1-O-Hexadecyl-2-O-acetyl-sn-glycerol is an alkyl acylglycerol that may activate the amino acid transport activity of the A-system and stimulate the absorption of methylaminoisobutyric acid (MeAIB). MeAIB inhibits mTOR phosphorylation, which may affect intestinal amino acid absorption and signal transduction .
    1-O-Hexadecyl-2-O-acetyl-sn-glycerol
  • HY-W010162R
    H-Ala-Ala-OH (Standard)

    L-Alanyl-L-alanine (Standard); Ala-Ala (Standard)

    		 Amino Acid Derivatives Reference Standards Others
    H-Ala-Ala-OH (L-Alanyl-L-alanine; Ala-Ala) (Standard) is the analytical standard of H-Ala-Ala-OH (L-Alanyl-L-alanine; Ala-Ala). This product is intended for research and analytical applications. H-Ala-Ala-OH (L-Alanyl-L-alanine; Ala-Ala) is a nonpolar dipeptide that is absorbed by human intestinal Caco-2 cells. The transport of alanine (Ala), like proton/amino acid symport, can lead to cytoplasmic acidification .
    H-Ala-Ala-OH (Standard)
  • HY-B1264R
    Celiprolol hydrochloride (Standard)

    		Reference Standards NO Synthase Adrenergic Receptor Cardiovascular Disease
    Celiprolol (hydrochloride) (Standard) is the analytical standard of Celiprolol (hydrochloride). This product is intended for research and analytical applications. Celiprolol (REV 5320) is a potent, cardioselective and orally active β1-andrenoceptor r antagonist with partial β2 agonist activity, with Ki values of 0.14-8.3 μM. Celiprolol has antihypertensive and antianginal activity, and can be used for the research of cardiovascular disease such as high blood pressure .
    Celiprolol hydrochloride (Standard)
  • HY-107969R
    Haloperidol decanoate (Standard)

    		Dopamine Receptor Reference Standards COX NO Synthase Neurological Disease
    Haloperidol decanoate (Standard) is the analytical standard of Haloperidol decanoate. This product is intended for research and analytical applications. Haloperidol decanoate is a depot preparation of haloperidol, a commonly used butyrophenone derivative with antipsychotic activity. Haloperidol decanoate can increase the striatal D2 receptor in rat. Haloperidol decanoate can improve conditions of psychoses (mainly schizophrenia). Haloperidol decanoate can lead to increased accumulation of the dopamine metabolites homo-vanillic acid. Haloperidol decanoate can reduce intestinal transport, increase gastric emptying and reduce acid output in rat model .
    Haloperidol decanoate (Standard)
  • HY-B0113AR
    Omeprazole sodium (Standard)

    H 16868 sodium (Standard)

    		 Reference Standards Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Metabolic Disease Cancer
    Omeprazole (sodium) (Standard) is the analytical standard of Omeprazole (sodium). This product is intended for research and analytical applications. Omeprazole sodium (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole sodium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sodium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sodium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sodium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sodium aslo has neuroprotective and antibacterial effects .
    Omeprazole sodium (Standard)
  • HY-B0113S4
    Omeprazole-d3 sodium

    H 16868-d3 sodium

    		 Isotope-Labeled Compounds Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Metabolic Disease Cancer
    Omeprazole-d3 sodium is deuterated labeled Omeprazole (HY-B0113). Omeprazole sodium (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole sodium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sodium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sodium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sodium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sodium aslo has neuroprotective and antibacterial effects .
    Omeprazole-d3 sodium
  • HY-B0113S2
    Omeprazole sulfone (methoxy-d3)

    Omeprazole sulphone (methoxy-d3)

    		 Isotope-Labeled Compounds Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Cancer
    Omeprazole sulfone (methoxy-d3) is the deuterium labeled Omeprazole sulfone. Omeprazole sulfone (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole sulfone competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sulfone inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sulfone inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sulfone alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sulfone aslo has neuroprotective and antibacterial effects .
    Omeprazole sulfone (methoxy-d3)
  • HY-B0113S5
    Omeprazole-d6

    H 16868-d6

    		 Isotope-Labeled Compounds Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Metabolic Disease Cancer
    Omeprazole-d6 (H 16868-d6) is deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .
    Omeprazole-d6
  • HY-B0113S1
    Omeprazole-d3-1

    H 16868-d3-1

    		 Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Metabolic Disease Cancer
    Omeprazole-d3-1 is the deuterium labeled Omeprazole. Omeprazole-1 (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole-1 competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole-1 inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole-1 inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole-1 alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole-1 aslo has neuroprotective and antibacterial effects .
    Omeprazole-d3-1
  • HY-P11740
    VYPFPGPIHN

    		Angiotensin-converting Enzyme (ACE) Drug Intermediate Others
    VYPFPGPIHN is a precursor peptide of β-casomorphin (HY-P0179) and also an ACE inhibitor (IC50 = 123 μM). VYPFPGPIHN resists hydrolysis by peptidases associated with intestinal cell monolayers, maintaining structural integrity and ACE inhibitory activity. VYPFPGPIHN is not extensively taken up or transported by differentiated intestinal cell monolayers .
    VYPFPGPIHN
  • HY-W344531
    Indomethacin glucuronide

    		Drug Metabolite Inflammation/Immunology
    Indomethacin glucuronide is a glucuronide metabolite of Indomethacin (HY-14397) .
    Indomethacin glucuronide
  • HY-182689
    LY3358966

    		Sodium Phosphate Cotransporter Metabolic Disease Endocrinology
    LY3358966 is an orally active sodium-dependent phosphate cotransporter 2b (NPT2b) inhibitor with a human IC50 of 32.4 nM, mouse IC50 of 43.9 nM, and rat of IC50 26.8 nM. LY3358966 inhibits NPT2b-mediated intestinal phosphate transport, decreases acute phosphate uptake into plasma, and increases fecal phosphate excretion. LY3358966 can be used for the research of renal disease .
    LY3358966
  • HY-114118F4
    Semaglutide-FITC

    Semaglutide-Lys(FITC)

    		 Fluorescent Dye GLP Receptor Metabolic Disease
    Semaglutide-FITC (Semaglutide-Lys(FITC)) is a FITC-labeled Semaglutide (a GLP-1R agonist) (HY-114118). Semaglutide-FITC can be used to directly track the distribution, cellular uptake, and transmembrane transport process of vesicles through techniques such as fluorescence imaging and flow cytometry. Semaglutide-FITC can be employed to study the movement and penetration ability of mixed vesicles in porcine intestinal mucus in vitro .
    Semaglutide-FITC
  • HY-159201
    24-Oxo-25-hydroxyvitamin D3

    		Calcium Channel Metabolic Disease
    24-Oxo-25-hydroxyvitamin D3 is a vitamin D3 metabolite and an intermediate in the renal mitochondrial side-chain oxidation pathway. 24-Oxo-25-hydroxyvitamin D3 enhances intestinal calcium transport in rats . 24-Oxo-25-hydroxyvitamin D3 can be used in studies related to X-linked hypophosphatemic rickets .
    24-Oxo-25-hydroxyvitamin D3
  • HY-131286
    Talaglumetad

    LY-544344

    		 mGluR Neurological Disease
    Talaglumetad (LY-544344) is an orally active prodrug of Eglumegad (HY-18941) and a metabotropic glutamate receptor 2/3 (mGluR2/3) agonist. Talaglumetad undergoes transmembrane transport via the intestinal peptide transporter hPepT1, and is enzymatically hydrolyzed to produce L-alanine and the parent drug Eglumegad after entering the body. Talaglumetad can be used in research related to metabotropic glutamate receptor 2-associated neurological systems .
    Talaglumetad
  • HY-13774
    WK-X-34

    		P-glycoprotein BCRP Cancer
    WK-X-34 is a low-toxicity, highly effective multidrug resistance reversal agent. By potently inhibiting the transport functions of P-glycoprotein (P-gp, ABCB1) and breast cancer resistance protein (BCRP), WK-X-34 significantly increases the intracellular accumulation of anticancer drugs and radiotracers in drug-resistant cells. WK-X-34 exerts no significant effect on MRP transporters. WK-X-34 not only restores the chemosensitivity of multidrug-resistant ovarian cancer cells, but also significantly enhances the uptake of 99mTc-Sestamibi in P-gp-positive xenograft tumors, brain and intestinal tissues. WK-X-34 exhibits extremely low toxicity and favorable safety profiles both in vitro and in mice (at doses up to 50 mg/kg), and can be used for research on overcoming multidrug resistance in ovarian cancer .
    WK-X-34

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: